MLchartDataset catalogue

Linagliptin

Term · Oncology and biomedicine · MLC-T-ONC-014787

A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. The inhibition of DPP-4 by linagliptin appears to be longer lasting than that by some other DPP-4 inhibitors tested.

Table 1. Record
IdentifierMLC-T-ONC-014787
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON 
{
  "id": "MLC-T-ONC-014787",
  "term": "Linagliptin",
  "field": "Oncology and biomedicine",
  "definition": "A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. The inhibition of DPP-4 by linagliptin appears to be longer lasting than that by some other DPP-4 inhibitors tested.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/linagliptin/"
}

Record 10,121 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.